Appendix Table 2b:
Additional baseline data from RCTs-Geography, age symptom onset
| Study | Enrollment Period | Study months | Geography | Enrolled | age over 65 n(%) | age over 60 n(%) | age over 50 n(%) | symptoms <= 8 days n(%) | symptoms <=7 days n(%) | symptoms <= 5 days n(%) | symptoms <= 3 days n(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CCP-CONV-ert7 | Nov 10 2020–July 28 2021 | 9 | Spain | 376 | 376 (100) | 376 (100) | |||||
| CCP-COV-Early13 | Netherlands | 406 | 351 (86) | 406 (100) | |||||||
| CCP-C3PO4 | Aug 2020-Feb 2021 | 7 | USA | 511 | 511 (100) | 511 (100) | 246 (48) | ||||
| CCP-Argentina5 | Jun 4 2020 – Oct 25 2020 | 5 | Argentina | 160 | 160 (100) | 160 (100) | |||||
| CCP-CSSC-0043 | June 3 2020-Oct 2021 | 16 | USA | 1225 | 80 (7) | 410 (35) | 1181 (100) | 517 (44) | |||
| Bamlanivimab-BLAZE-114 | June 2020-Aug 2020 | 3 | USA | 467 | 53 (12) | 226 (50)mean | |||||
| Sotrovimab-COMET-ICE8 | Aug 27 2020-March 2021 | 6 | United States, Canada, Brazil, and Spain | 1057 | 211(20) | 1057 (100) | 624 (59) | ||||
| Bamlanivimab/etesevimab-BLAZE-115 | Sept 2020-Dec 2020 | 3 | USA | 1035 | 323 (31) | 979 (95) | |||||
| Casirivimab/imdevimab-REGEN-COV Ph 316 | Sept 24 2020-Jan 17 2021 | 4 | USA Mexico | 2696 | 358 (13) | 2696 (100) | 1489 (66) | ||||
| Casirivimab/imdevimab-REGEN-COV Ph 1/217 | June 16, 2020 – Sept 23, 2020 | 3 | USA | 799 | 799 (100) | 599 (75) | 400 (50) | ||||
| Bebtelovimab-BLAZE-41 | May 2021-July 2021 | 3 | USA | 253 | 1 (<1) | 253 (100) | |||||
| Regdanvimab-CT-P5918 | Oct 2020-Dec 2020 | 2 | South Korea, Romania, Spain, USA | 327 | 85 (26) | 327 (100) | |||||
| Regdanvimab-CT-P59–219 |
Jan 18 2021 to april 24 2021 | 3 | world wide | 1315 | 297 (23) | 986 (75) | 329 (25) | ||||
| Tixagevimab–cilgavimab-TACKLE20 | Jan 28, 2021–July 22, 2021, | 6 | USA, Latin America, Europe, and Japan. | 1014 | 116 (13) | 910 (100) | |||||
| Molnupiravir-MOVe-OUT21 | May 2021–Oct 2021 | 6 | worldwide | 1433 | 246 (17) | 1408 (100) | 674 (48) | ||||
| Molnupiravir-PANORAMIC22 | Dec 8–2021 – April 27, 2022 | 5 | UK | 25783 | 6838 (27) | 22510 (87) | |||||
| Molnupiravir-Aurobindo23 | July 1, 2021 – Aug 24, 2021 | 2 | India | 1220 | 661 (54) | ||||||
| Nirmatrelvir/ritonavir-EPIC-HR9 | July 1 2021 – Dec 2021 | 6 | worldwide | 2246 | 287(12.8) | 2246 (100) | 1489 (66.3) | ||||
| Remdesivir-PINETREE12 | Sept 2020-Apr 2021 | 8 | USA, Spain, Denmark UK | 562 | 170 (30) | 562 (100) | |||||
| Interferon Lambda-TOGETHER24 | Jun 24 2021-feb 7 2022 | 8 | Brazil | 1949 | 752 (39) | 1949 (100) | 1158 (59) | ||||
| Interferon Lambda-ILIAD25 | May 18, 2020–Sep 4 2020 | 4 | Canada | 60 | 60 (100) | ||||||
| Interferon Lambda-COVID-Lambda26 | Apil 25 2020-July 7 2020 | 2 | USA | 120 | |||||||
| Sofosbuvir and daclatasvir-SOVODAK27 | April 8 2020-May 19 2020 | 1 | Iran | 55 | |||||||
| Favipavir-Avi-Mild-1928 | July 23, 2020–Aug 4 2021 | 12 | Saudi Arabia | 245 | 30 (13) | 231 (100) | |||||
| Favipiravir-Iran29 | Dec 5 2020-mar 31 2021 | 4 | Iran | 77 | 77 (100) | ||||||
| Favipiravir-FLARE30 | Oct 6 2020–Nov 4 2021 | 13 | United Kingdom | 119 | 119 (100) | 76 (64) | |||||
| Favipiravir/Lopinavir/Ritonavir-FLARE30 | Oct 6 2020–Nov 4 2021 | 13 | United Kingdom | 121 | 121 (100) | 80 (66) | |||||
| Lopinavir/Ritonavir-FLARE30 | Oct 6 2020–Nov 4 2021 | 13 | United Kingdom | 120 | 120 (100) | 75 (63) | |||||
| Lopinavir/ritonavir-TREAT NOW31 | Jun 2020-Dec 2021 | 18 | USA | 446 | 13 (3) | 112 (25) | 446 (100) | 349 (78) | 124 (28) | ||
| Lopinavir/ritonavir-TOGETHER32 | June 2 2020-Oct 9 2020 | 4 | Brazil | 471 | 275 | 471 (100) | 74 (16) | ||||
| Tenofovir Disproxil Fumarate Plus Emtricitabine-AR0-CORONA33 |
Nov 20 2020-Mar 19 2021 | 4 | France | 60 | 60 (100) | 45 (75) | |||||
| Metformin-COVID-OUT34 | Dec 30 2020 – Jan 28 2022 | 13 | USA | 1323 | 1197 (100) | ||||||
| Metformin-TOGETHER35 |
jan 15 2021–April 13 2021 | 3 | Brazil | 418 | 234 (56) | 418 (100) | 184 (44) | ||||
| Fluvoxamine-TOGETHER11 | Jan 2021 – Aug 2021 | 8 | Brazil | 1497 | 655 (44) | 1497 (100) | 638 (43) | ||||
| Fluvoxamine-STOP COVID36 | April 10 2020 – Aug 5 2020 | 4 | USA | 152 | 152 (100) | 114 (75) | |||||
| Fluvoxamine-COVID-OUT34 | Dec 30 2020 – Jan 28 2022 | 13 | USA | 661 | 733 (100) | ||||||
| Fluvoxamine ACTIV-637 | Au 6 2021-May 27 2022 | 10 | USA | 1288 | 541 (42) | 966 (75) | 644 (50) | ||||
| Fluvoxamine/budesonide-TOGETHER38 | Jan 15 2022-July 6 2022 | 6 | Brazil | 1476 | 829 (56) | 1476 (100) | 917 (62) | ||||
| Ivermectin-TOGETHER39 | March 23 – Aug 2 2021 | 5 | Brazil | 1358 | 1358 (100) | 597 (44) | |||||
| Ivermectin-COVID-OUT34 | Dec 30 2020 – Jan 28 2022 | 13 | USA | 808 | 592 (100) | ||||||
| Ivermectin Iran40 | Feb 19 21 – Aug 30 21 | 7 | Iran | 582 | 291 (50) | ||||||
| Ivermectin-ACTIV-641 | June 23 2021 – Feb 4 2022 | 7 | USA | 1591 | 680 (43) | 1193 (75) | |||||
| Ivermectin high dose-ACTIV-642 |
feb 16 2022-July 22 2022 | 5 | USA | 1206 | 905 (75) | 603 (50) | 302 (25) | ||||
| Hydroxychloroquine-TOGETHER32 | June 2 2020-Oct 9 2020 | 4 | Brazil | 441 | 262 (59) | 441 (100) | 77 (17) | ||||
| Hydroxychloroquine-COVID-19 PEP43 | March 22 2020 – May 20 2020 | 2 | USA Canada | 491 | 99 (20) | 423 (100) | |||||
| Hydroxychloroquine-AH COVID-1944 | April 15 2020–May 22 2020 | 1 | Canada | 148 | |||||||
| Hydroxychloroquine-BCN PEP-CoV-245 | March 17 2020-May 26 2020 | 2 | Spain | 293 | 293 (100) | ||||||
| Hydroxychloroquine-BMG46 | April 15 2020-July 27 2020 | 3 | USA | 231 | 23 (10) | 143 (62) | 85 (37) | ||||
| Hydroxychloroquine-Utah47 | Apr 2020-Apr 2021 | 12 | USA | 303 | |||||||
| Hydroxychloroquine/Azithromycin-Brazil48 | Apr 12 2020-May 13 2020 | 1 | Brazil | 83 | 84 (100) | ||||||
| Nitazoxanide-Romark49 | Aug 2020–Jan 2021 | 5 | USA Peurto rico | 379 | 379 (100) | ||||||
| Colchicine-COLCORONA2 | March 2020-Dec 2020 | 9 | Brazil, Canada, Greece, South Africa, Spain, and the USA | 4488 | 1122 (25) | 3590 (80) | |||||
| Losartan-MN50 |
Apr 2020-Nov 2020 | 8 | USA | 117 | 3 | 117 (100) | 106 | ||||
| Niclosamide51 | Oct 1 2020-April 20 2021 | 7 | USA | 73 | 67 (100) | ||||||
| Aspirin-ACTIV-4B52 | Sept 1 2020 – June 17 2021 | 10 | USA | 328 | ~82 (25) | 82 (25) | |||||
| 2.5-mg apixaban-ACTIV-4B52 | Sept 1 2020 – June 17 2021 | 10 | USA | 329 | ~82 (25) | 82 (25) | |||||
| 5-mg apixaban ACTIV-4B52 | Sept 1 2020 – June 17 2021 | 10 | USA | 328 | ~82 (25) | 82 (25) | |||||
| Sulodexide53 | June 5 2020 – August 5 2020 | 2 | Mexico | 243 | 243 (100) | ||||||
| Enoxaparin-ETHIC54 | Oct 27 2020 – Nov 8 2021 | 12 | Belgium, Brazil, India, South Africa, Spain, and the UK). | 219 | 164 (75) | 121 (50) | |||||
| Enoxaparin-OVID55 | Aug 5 2020-Jan 14 2022 | 17 | Switzerland and Germany | 572 | 572 (100) | 429 (dx 75) | |||||
| Inhaled Ciclesonide-COVIS56 |
jun 11 2020-nov 3 2020 | 5 | USA | 400 | |||||||
| Inhaled ciclesonide-COVERAGE57 | Dec 29 2020-July 22 2021 | 7 | France | 217 | 151 (70) | 217 (100) | 217 (100) | ||||
| Zinc58 | Apr 27 2020-Oct 14 2020 | 6 | USA | 108 | |||||||
| Ascorbic acid58 | Apr 27 2020-Oct 14 2020 | 6 | USA | 98 | |||||||
| Zinc/Ascorbic acid58 | Apr 27 2020-Oct 14 2020 | 6 | USA | 108 | |||||||
| Homeopathy-COVID-Simile59 | Jun 29 2020-Ap 6 2021 | 10 | Brazil | 86 | |||||||
| Saliravira60 | Dec 21 2020 – March 1 2021 | 3 | Iran | 143 | |||||||
| Azithromycin-Atomic261 | June 3, 2020–Jan 29, 2021, | 8 | UK | 292 | |||||||
| Azithromycin-ACTION62 | May 22 2020 – March 16 2021 | 9 | USA | 197 | 18 (9) | 197 (100) | |||||
| Resveratrol63 | September 13, 2020 – December 11, 2020, | 3 | USA | 100 | 16 (16) | 50 (50) |